US2022267477A1PendingUtilityA1

Methods of making multispecific antigen-binding molecules

Assignee: REGENERON PHARMAPriority: Apr 28, 2016Filed: May 4, 2022Published: Aug 25, 2022
Est. expiryApr 28, 2036(~9.8 yrs left)· nominal 20-yr term from priority
C07K 2317/77C07K 16/22C07K 2317/31C07K 16/44C07K 16/2896C07K 16/1203A61K 2039/505C07K 16/2866C40B 30/04C07K 16/468
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides multispecific antigen-binding molecules and methods of making or selecting same. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.

Claims

exact text as granted — not AI-modified
1 - 35 . (canceled) 
     
     
         36 . A library comprising a plurality of production cells, each transformed with a polynucleotide encoding an antibody light chain, a polynucleotide encoding a tag-specific binding protein heavy chain, and a different polynucleotide encoding a destroyer-specific binding protein heavy chain. 
     
     
         37 . The library of  claim 36 , wherein the destroyer-specific binding protein binds CD63. 
     
     
         38 . The library of  claim 36 , wherein the destroyer-specific binding protein binds APLP2. 
     
     
         39 . The library of  claim 36 , wherein the destroyer-specific binding protein binds ASGR1.

Join the waitlist — get patent alerts

Track US2022267477A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.